medigraphic.com
ISSN 2007-4360 (Print)
Asociación Mexicana de Periodontología, Colegio de Periodoncistas A.C

2014, Number 1

<< Back Next >>

Rev Mex Periodontol 2014; 5 (1)

Periodontal sickness prevalence among breast cancer patients at ISSEMyM Oncological Center

Ocampo GKG, Barrón GI, Barrera FJL, Nava BB

Language: Spanish
References: 25
Page: 20-24
PDF size: 211.40 Kb.


ABSTRACT

Introduction: Cytostatic treatment is one of the treatments of choice for breast cancer, which uses drugs that can affect cancer cells by preventing their proliferation and/or annihilating oral complications resulting from cell damage, such as development of periodontal disease in periodontally healthy patients or increase the severity of it. The aim of this study was to determine the prevalence of periodontal disease and oral manifestations in patient’s with breast cancer and cytostatic treatment, since the literature does not report the relationship between these two entities. Methods: A cross-sectional study was performed in 100 patients who accomplished the inclusion criteria of this study; IHOS rates, CPI, habit survey and review of medical records were applied in all of them. We looked for association with risk factors, which will be reported and later correlated. Results: We found that 95.1% (77) of the total patients had evidence of periodontal disease, using the IHO-S it was determined that 50.6% had detritus covering more than one third of tooth surface but less than two at a frequency (n) of 41; in 39.5% of patients were found that mucositis is one of the determining factors to trigger or aggravate periodontal disease during and after cytostatic treatment. Conclusions: The prevalence of periodontal disease is very high in patients under cytostatic treatment; it also comes with a higher degree of severity.


REFERENCES

  1. Martínez MF. Epidemiología del cáncer de cuello uterino. Medicina Universitaria. 2004; 6 (22): 39-46.

  2. Lazcano-Ponce EC, Hernández-Ávila M. Cáncer: frecuencia, factores de riesgo y medidas de prevención. Salud Pública Mex. 1997; 39 (4): 225-251.

  3. Brandan ME, Villaseñor-Navarro Y. Detección del cáncer de mama: estado de la mamografía en México. Revista del Instituto Nacional de Cancerología. 2006; 1 (3): 147-162.

  4. Datos proporcionados por INEGI 2009.

  5. Knaul FM, Nigenda G, Lozano R, Arreola-Órnelas H, Langer A, Frenk J. Cáncer de mama en México: una prioridad apremiante. Salud Pública Méx. 2009; 51 (Suppl 2): S335-S344.

  6. Otto E. Enfermería oncológica. 3a. ed. Madrid: Ed. Mosby; 1999. pp. 24-25.

  7. González-Barón M. Fundamentos de oncología médica. Madrid: Interamericana McGraw-Hill; 1989. pp. 41-47.

  8. Instituto Americano de Cancerología. Disponible en: www.aicr.org

  9. Pindborg JJ. Atlas de enfermedades de la mucosa oral. 5a ed. México, D.F., Ed. Masson; 1994: pp. 253-270.

  10. Smith C et al. Oral cancer epidemiology etiology and pathology. 3a ed. Chicago: Ed. Cancer series; 1990. pp. 17-41.

  11. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998; 34: 39-43.

  12. Luglie PF, Mura G, Mura A, Angius A, Soru G, Farris A. Prevention of periodontopathy and oral mucositis during antineoplastic chemotherapy. Clinical study. Minerva Stomatol. 2002; 51 (6): 231-239.

  13. Arce RM, Tamayo O, Cortés A. Apoptosis de fibroblastos gingivales en periodontitis. Colomb Med. 2007; 38 (3): 197-209. ISSN 1657-9534.

  14. Peña-Sisto M, Peña-Sisto L, Díaz-Felizola A, Torres-Keiruz D, Lao-Salas N. The periodontal disease as a risk for systemic diseases. Rev Cubana Estomatol. 2008: 45 (1). pp. 1-9.

  15. P Pindborg JJ. Atlas de enfermedades de la mucosa oral. 5a ed. México, D.F., Ed. Masson; 1994: pp. 253-270.

  16. Carrillo-Martínez J, Castillo-González M, Hernández-Rodríguez HG, Zermeño-Ibarra J. Estudio epidemiológico de las enfermedades periodontales en pacientes que acuden a la facultad de estomatología de la UASLP. ADM. 2000; 57 (6): 205-213.

  17. Mazzeo MA, Linares JA, Campos ML, Busamia BE, Dubersarsky C. Oral signs of intravenous chemotherapy with 5- fluorouracil and leucovorin calcium in colon cancer treatment. Med Oral Patol Oral Cir Bucal. 2009; 14 (3): E108-13.

  18. Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, Mac Phail L et al. Randomizad clinical trial of clorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum. 1996; 23: 921-927.

  19. Sabater-Recolons MM, López-López J, Rodríguez de Rivera-Campillo ME, Chimenos-Küstner E, Conde-Vidal JM. Estado bucodental y mucositis oral. Estudio clínico en pacientes con enfermedades hematológicas. Med Oral Patol Oral Cir Bucal. 2006; 11: E497-502.

  20. López-Galindo MP, Bagán JV, Jiménez-Soriano Y, Alpiste F, Camps C. Clinical evaluation of dental and periodontal status in a group of oncological patients before chemotherapy. Med Oral Patol Oral Cir Bucal. 2006; 11: E17-21.

  21. Martínez MF. Epidemiología del cáncer de cuello uterino. Medicina Universitaria. 2004; 6 (22): 39-46.

  22. Ingleli T, Ören H, Uysal K. The acute effects of chemotherapy upon the oral cavity: prevention and management. Turk J Cancer. 2001; 31 (3): 93-105.

  23. Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nurs. 1990; 13: 345-552.

  24. Pitten FA, Kiefert T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chorhexidine based oral rinse? A double-blind, block-randomized, controlled study. J Hosp Inf. 2003; 53: 283-291.

  25. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis and management. Oncology. 2003; 17: 1787-1789.




2020     |     www.medigraphic.com